Cost ‑effectiveness of add‑on dapagliflozin for heart failure with reduced ejection fraction patients without diabetes

CONCLUSIONS: Adding dapagliflozin to SoC is likely to be a cost-saving therapy for patients with HFrEF and without T2DM in Qatar.PMID:38390641 | DOI:10.1080/13696998.2024.2322258

Source: Journal of Medical Economics - February 23, 2024 Category: Health Management Authors: Dina Abushanab Salma Chbib Rasha Kaddoura Moza Al Hail Palli Valappila Abdul Rouf Wessam El-Kassem Jassim Shah Ramesh Nair Daoud Al-Badriyeh Source Type: research